GATINEAU, QC --(Marketwired - March 29, 2017) - The Hydropothecary Corporation
(TSX VENTURE: THCX) (the "Company"), a licensed producer and distributor of medical cannabis, is
pleased to announce it has received an amendment to its licence from Health Canada under the Access to Cannabis for Medical
Purposes Regulations (Canada) (the "ACMPR") to include the sale of cannabis oils from its facility in Gatineau, QC. The
Company's license under the ACMPR was amended from production only and provides the Company with the ability to sell cannabis oil
products to registered patients under the ACMPR along with its current dried medical cannabis products.
The Company received an amendment to its licence under the ACMPR to produce cannabis oils in August 2015 and has been focused
on the development of a new innovative oil product line. In anticipation of this approval to sell cannabis oil extracts, the
Company has been producing cannabis oil and extracts. Sales are anticipated to begin late Spring 2017.
"This is another significant milestone in the Hydropothecary growth story and provides our clients with yet another way in
which to consume their medicinal cannabis without smoking" said Sebastien St-Louis, Co-Founder and Chief Executive Officer.
About The Hydropothecary Corporation
The Hydropothecary Corporation is an authorized licensed producer and distributor of medical marijuana licensed by Health
Canada under the Access to Cannabis for Medical Purposes Regulations (Canada). Hydropothecary provides naturally grown
and rigorously tested medical marijuana of uncompromising quality. Hydropothecary's branding, marijuana product offering, patient
service standards and product pricing are consistent with THC's positioning as a premium brand for a legal source for medical
marijuana within this new marketplace. In addition to medical marijuana production and sales, Hydropothecary explores various
research and development opportunities for cannabinoid extracts, drugs and combinatory chemistry. In addition, the company is
investigating the development and patenting of novel technologies related to medical marijuana, as well as the import and export
of medical marijuana.
Forward-Looking Information
This press release contains forward-looking information based on current expectations.
Statements about market making activities and TSXV approvals, among others, are forward-looking information. These statements
should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties
and other factors that may cause actual results, performance or achievements to be materially different from those implied by
such statements. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or
circumstances unless required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of
the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.